Rchr
J-GLOBAL ID:201901020005834933   Update date: May. 13, 2024

Kagabu Masahiro

カガブ マサヒロ | Kagabu Masahiro
Affiliation and department:
Research field  (1): Obstetrics and gynecology
Research keywords  (2): Cancer Immunology ,  Gynecologic oncology
Research theme for competitive and other funds  (5):
  • 2022 - 2025 子宮癌肉腫に対する免疫逃避改善を誘導するウイルス療法の開発
  • 2021 - 2024 Development of tumor-host integrative therapies to overcome the refractory nature of uterine serous carcinoma
  • 2019 - 2022 卵巣明細胞癌に対するNEFHを標的とした新規治療法の開発
  • 2016 - 2019 The KANK1 pathway may be a novel therapeutic target for ovarian clear cell carcinoma
  • 2016 - 2019 Development of new viral therapy for improvement of immune escape mechanism in ovarian cancer
Papers (56):
  • Yohei Chiba, Masahiro Kagabu, Mitsumasa Osakabe, Rikako Ito, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Tadahiro Shoji, Naoki Yanagawa, et al. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Japanese journal of clinical oncology. 2024. 54. 4. 424-433
  • Takayuki Nagasawa, Tadahiro Shoji, Eriko Takatori, Yoshitaka Kaido, Masahiro Kagabu, Dai Shimizu, Tatsuhiko Shigeto, Tsukasa Baba, Toru Sugiyama, Yoshihito Yokoyama. A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study). Cancers. 2023. 15. 21. 5201-5201
  • Tsukasa Baba, Masafumi Koshiyama, Masahiro Kagabu, Yoshiki Mikami, Sachiko Minamiguchi, Suzuko Moritani, Mitsuya Ishikawa, Aikou Okamoto, Yasuhisa Terao, Toru Nakanishi, et al. Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study. International journal of clinical oncology. 2023. 28. 10. 1411-1420
  • Hidehiko Akashi, Nozomi Yachida, Haruka Ueda, Manako Yamaguchi, Kaoru Yamawaki, Ryo Tamura, Kazuaki Suda, Tatsuya Ishiguro, Sosuke Adachi, Yoshikazu Nagase, et al. SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Molecular cancer therapeutics. 2023
  • Marina Abe, Tadahiro Shoji, Yohei Chiba, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Fumiaki Takahashi, Takeshi Aida, Tsukasa Baba. Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer research. 2023. 43. 3. 1265-1272
more...
MISC (67):
more...
Books (6):
  • 婦人科がん薬物療法パーフェクトガイド
    診断と治療社 2021 ISBN:9784787824806
  • 産婦人科専門医のための必修知識
    日本産科婦人科学会事務局 2020 ISBN:9784907890223
  • エビデンスに基づいた癌化学療法ハンドブック
    メディカルレビュー社 2018 ISBN:4896007344
  • 産婦人科手術スタンダード
    メジカルビュー社 2017 ISBN:9784758317436
  • EBMがん化学療法・分子標的治療法
    中外医学社 2015 ISBN:9784498022461
more...
Education (2):
  • 1996 - 2000 Iwate Medical University Graduate School of Medical Science
  • 1990 - 1996 Iwate Medical University School of Medicine
Professional career (1):
  • 医学博士 (岩手医科大学)
Work history (9):
  • 2023/04 - 現在 Iwate Medical University
  • 2020/07 - 2023/03 Iwate Medical University School of Medicine
  • 2017/01 - 2020/06 Iwate Medical University
  • 2009/09 - 2016/12 Iwate Medical University
  • 2007/09 - 2009/08 University of Pennsylvania Ovarian Cancer Research Center visiting assistant professor
Show all
Committee career (3):
  • 2022/01 - 現在 日本婦人科ロボット手術学会 幹事
  • 2020/09 - 現在 日本婦人科腫瘍学会 子宮頸がん治療ガイドライン2022年版改訂委員会作成幹事
  • 2019/06 - 現在 日本臨床細胞学会 利益相反員会
Association Membership(s) (7):
日本がん免疫学会 ,  日本臨床細胞学会 ,  日本癌治療学会 ,  日本癌学会 ,  日本婦人科腫瘍学会 ,  日本産婦人科医会 ,  日本産科婦人科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page